POSC106 Budget Impact Analysis of Including Sacubitril/Valsartan in the National Formulary for the Treatment of Heart Failure with Reduced Ejection Fraction (HFREF) in Thailand
Abstract
Authors
K Ratanasumawong D Piyayotai P Makarawate